title: Hyperlipidaemia and cardiovascular disease -- newer antihyperglycaemic agents and cardiovascular disease.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Peter
authors.forename: Hammad
authors.initials: H
authors.lastname: Bajwa
authors.forename: Sony
authors.initials: S
authors.lastname: Anthony
mesh_terms: D001559:Benzhydryl Compounds; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives; D005960:Glucosides / Q000494:pharmacology; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D012307:Risk Factors; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D016896:Treatment Outcome
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin; D052216:Glucagon-Like Peptide 1